Electra Therapeutics raised $350 million in an upsized Nasdaq IPO to support late-stage development of ipsoprubart, a pan-SIRP monoclonal antibody in secondary hemophagocytic lymphohistiocytosis (sHLH). The offering priced at $15 per share and provided incremental funding tied to its path toward a future BLA filing. The IPO comes as the company positions itself for commercial readiness, with the lead asset aimed at an indication where inflammation biology and immune-cell regulation are central. Market coverage noted that Electra’s pricing and proceeds bucked some broader IPO pacing expectations for 2026. For investors, the deal consolidates risk around a single late-stage program while giving the company runway for registrational timelines and manufacturing scale needs often associated with late-phase antibody development.